Printer Friendly

Acadia Pharmaceuticals Phase II Study of Pimavanserin in Alzheimer's Disease Meets Primary Endpoint of Psychosis Reduction.

M2 PHARMA-November 6, 2017-Acadia Pharmaceuticals Phase II Study of Pimavanserin in Alzheimer's Disease Meets Primary Endpoint of Psychosis Reduction

(C)2017 M2 COMMUNICATIONS

- San Diego, California-based central nervous system disorders therapeutics developer Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) presented data from its Phase II -019 Study of pimavanserin in Alzheimer's disease psychosis at a symposium at the 10th Clinical Trials on Alzheimer's Disease meeting in Boston, the company said.

The Phase II -019 Study was a double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of pimavanserin in 181 patients with Alzheimer's disease psychosis.

Pimavanserin met the primary endpoint in the study, showing a statistically significant reduction in psychosis versus placebo as measured by the Neuropsychiatric Inventory-Nursing Home (NPI-NH).

No detrimental effect was observed on cognition for pimavanserin-treated patients compared to placebo. Atypical antipsychotics have been associated with a statistically significant acceleration of cognitive deterioration in patients with Alzheimer's disease.

Data presented at CTAD from a pre-specified subgroup analysis demonstrated a substantively larger and significant reduction in psychosis in pimavanserin-treated patients with more severe psychosis, further underscoring the effect seen on the primary result.

Pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors thought to play an important role in dementia-related psychosis, is being evaluated in an extensive clinical development program by Acadia across multiple indications.

Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Clinical report
Date:Nov 6, 2017
Words:252
Previous Article:Alexion Data Show 80% of Infants with LAL-D Treated with Kanuma (sebelipase alfa) Survive Beyond 1 Year of Age.
Next Article:UroGen Pharma and Allergan enrol first patient in Phase 2 clinical trial of RTGel/BOTOX.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters